Cytokinetics Inc vs Pinterest Inc — how do they compare? Cytokinetics Inc trades at $76.29 (market cap $10.63B), while Pinterest Inc trades at $22.95 (market cap $13.45B). The key difference: Pinterest Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | PINS | |
|---|---|---|
Market Cap | $10.63B | $13.45B |
Sector | Technology | Media |
52-Week High | $87.26 | $37.95 |
52-Week Low | $34.31 | $15.42 |
Enterprise Value | $10.74B | $13.37B |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Pinterest (PINS) trades at $22.90, down 6.03% over 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $0.43, beating estimates of $0.36, driven by 18% revenue growth and record monthly active users. However, the stock faces pressure from lukewarm Q3 revenue guidance and competitive ad market concerns.
The outlook remains positive with strong analyst support—54% recommend Buy—and a $28.69 consensus price target implying 25% upside. Key risks include intense advertising competition and potential growth deceleration, but fundamentals are solid with revenue climbing to $4.22B in 2025 and a robust 79.47% gross margin.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →